Koyama, Shohei
Akbay, Esra A.
Li, Yvonne Y.
Herter-Sprie, Grit S.
Buczkowski, Kevin A.
Richards, William G.
Gandhi, Leena
Redig, Amanda J.
Rodig, Scott J.
Asahina, Hajime
Jones, Robert E.
Kulkarni, Meghana M.
Kuraguchi, Mari
Palakurthi, Sangeetha
Fecci, Peter E.
Johnson, Bruce E.
Janne, Pasi A.
Engelman, Jeffrey A.
Gangadharan, Sidharta P.
Costa, Daniel B.
Freeman, Gordon J.
Bueno, Raphael
Hodi, F. Stephen
Dranoff, Glenn
Wong, Kwok-Kin
Hammerman, Peter S.
Article History
Received: 9 August 2015
Accepted: 21 December 2015
First Online: 17 February 2016
Competing interests
: G.D. received sponsored research support from Bristol-Myers Squibb and Novartis. He is currently an employee of Novartis. F.S.H. is a Bristol-Myers Squibb nonpaid consultant, Novartis, Merck and Genentech consultant and receives clinical trial support to the institution from these companies. G.J.F. receives patent royalties on the PD-1 pathway from Bristol-Myers-Squibb, Roche, Merck, EMD-Serrono, Boehringer-Ingelheim, Amplimmune/AstraZeneca and Novartis and patent royalties on the TIM-3 pathway from Novartis. D.B.C. is a consultant for Pfizer. S.J.R. receives research support from Bristol-Myers Squibb and the Center for Immune Oncology, DFCI. The remaining authors declare no competing financial interests.